Vuolanto visited the UK for networking. The research professor from the funder Funding boost for promising treatment | Parkinson's UK describes Phase 1b as having been highly successful. They have likely studied it more thoroughly than what Vuolanto’s presentation there showed.
This brought to mind: The Phase 1b biomarker announcement stated that HER-096 had a clear systemic effect, which is naturally promising for many other potential applications besides Parkinson’s, but the central nervous system effects at the biomarker level remained unclear—how they were measured and what was observed—or do others have a different understanding? The analysis was indeed promised to take months.